Home / Market News / $BMY
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $61 From $63

Oct 30, 2026, 3:03 PM UTC · Primary ticker $BMY

Goldman Sachs has lowered its price target for Bristol-Myers Squibb (BMY) stock from $63 to $61. This adjustment indicates a slightly less optimistic valuation from the firm, which could exert minor downward pressure on BMY's share price in the short term.

Goldman Sachs has revised its price target for Bristol-Myers Squibb (BMY) down to $61 from $63. This analyst action reflects a re-evaluation of the biopharmaceutical company's prospects by a major investment bank. While not a drastic change, a price target reduction from a prominent firm like Goldman Sachs can signal a slight decrease in investor confidence or a more conservative outlook on future earnings or growth. This primarily affects current and potential BMY shareholders, potentially leading to minor short-term selling pressure as some investors may adjust their positions. Long-term implications are likely minimal unless this is part of a broader trend of analyst downgrades or reflects fundamental shifts not yet apparent.

$BMY negative Price target reduction
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.